Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival. Roche’s Genentech division has reported that Tecentriq, plus Avastin, was unable to improve progression-free survival as a front-line treatment ... The phase 3 IMagyn050 study evaluated the

AZ’s comeback drug cediranib stumbles in phase 3 trial

Cediranib has been developed as a potential oral alternative to drugs like Roche’s big-selling injectable VEGF inhibitor Avastin (bevacizumab), which is already used to treat ovarian cancer and other

FDA accepts review to broaden GSK’s Zejula label

Lynparza, like Zejula, has data which backs up its use in ‘all-comer’ ovarian cancer patients – when added to Avastin (bevacizumab), the standard of care for ovarian cancer, the treatment improved ... progression free survival by a median of 22.1

FDA sets June decision date for Tecentriq monotherapy in NSCLC

It is indicated for use in combination with chemotherapy and Roche’s older cancer antibody Avastin (bevacizumab) as a first-line treatment for non-squamous NSCLC.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]